Pluripotent embryonic stem cells and multipotent adult germline stem …

Title & authors Abstract Similar articles Cited by Publication types MeSH terms Related information LinkOut - more resources . 2010 Nov;16(11):846-55. doi: 10.1093/molehr/gaq060. Epub 2010 Jul 12.

Affiliations Expand

Item in Clipboard

S Meyeret al. Mol Hum Reprod. 2010 Nov.

Display options

Format Abstract PubMed PMID

Item in Clipboard

Display options

Format Abstract PubMed PMID

DNA microarray analysis was performed with mouse multipotent adult germline stem cells (maGSCs) and embryonic stem cells (ESCs) from different genetic backgrounds cultured under standard ESC-culture conditions and under differentiation-promoting conditions by the withdrawal of the leukemia inhibitory factor (LIF) and treatment with retinoic acid (RA). The analyzed undifferentiated cell lines are very similar based on their global gene expression pattern and show 97-99% identity dependent on the analyzed background. Only 621 genes are differentially expressed in cells derived from mouse 129SV-background and 72 genes show differences in expression in cells generated from transgenic Stra8-EGFP/Rosa26-LacZ-background. Both maGSCs and ESCs express the same genes involved in the regulation of pluripotency and even show no differences in the expression level of these genes. When comparing maGSCs with previously published signature genes of other pluripotent cell lines, we found that maGSCs shared a very similar gene expression pattern with embryonic germ cells (EGCs). Also after differentiation of maGSCs and ESCs the transcriptomes of the cell lines are nearly identical which suggests that both cell types differentiate spontaneously in a very similar way. This is the first study, at transcriptome level, to compare ESCs and a pluripotent cell line derived from an adult organism (maGSCs).

Zovoilis A, Pantazi A, Smorag L, Opitz L, Riester GS, Wolf M, Zechner U, Holubowska A, Stewart CL, Engel W. Zovoilis A, et al. Mol Hum Reprod. 2010 Nov;16(11):793-803. doi: 10.1093/molehr/gaq053. Epub 2010 Jun 21. Mol Hum Reprod. 2010. PMID: 20566704

Zovoilis A, Nolte J, Drusenheimer N, Zechner U, Hada H, Guan K, Hasenfuss G, Nayernia K, Engel W. Zovoilis A, et al. Mol Hum Reprod. 2008 Sep;14(9):521-9. doi: 10.1093/molehr/gan044. Epub 2008 Aug 12. Mol Hum Reprod. 2008. PMID: 18697907

Nolte J, Michelmann HW, Wolf M, Wulf G, Nayernia K, Meinhardt A, Zechner U, Engel W. Nolte J, et al. Differentiation. 2010 Nov-Dec;80(4-5):184-94. doi: 10.1016/j.diff.2010.08.001. Epub 2010 Sep 1. Differentiation. 2010. PMID: 20810205

Kerr CL, Shamblott MJ, Gearhart JD. Kerr CL, et al. Methods Enzymol. 2006;419:400-26. doi: 10.1016/S0076-6879(06)19016-3. Methods Enzymol. 2006. PMID: 17141064 Review.

Petitte JN, Liu G, Yang Z. Petitte JN, et al. Mech Dev. 2004 Sep;121(9):1159-68. doi: 10.1016/j.mod.2004.05.003. Mech Dev. 2004. PMID: 15296979 Review.

Han Z, Zhang Q, Zhu Y, Chen J, Li W. Han Z, et al. Stem Cells Int. 2020 Jul 6;2020:8863539. doi: 10.1155/2020/8863539. eCollection 2020. Stem Cells Int. 2020. PMID: 32695182 Free PMC article. Review.

Kalasauskas D, Sorokin M, Sprang B, Elmasri A, Viehweg S, Salinas G, Opitz L, Rave-Fraenk M, Schulz-Schaeffer W, Kantelhardt SR, Giese A, Buzdin A, Kim EL. Kalasauskas D, et al. Cancers (Basel). 2020 Mar 1;12(3):570. doi: 10.3390/cancers12030570. Cancers (Basel). 2020. PMID: 32121554 Free PMC article.

Bai Y, Zhu C, Feng M, Wei H, Li L, Tian X, Zhao Z, Liu S, Ma N, Zhang X, Shi R, Fu C, Wu Z, Zhang S. Bai Y, et al. Stem Cell Res Ther. 2018 Jul 18;9(1):200. doi: 10.1186/s13287-018-0931-0. Stem Cell Res Ther. 2018. PMID: 30021628 Free PMC article.

Imamura M, Lin ZY, Okano H. Imamura M, et al. Reprod Med Biol. 2012 Jun 19;12(1):1-14. doi: 10.1007/s12522-012-0131-z. eCollection 2013 Jan. Reprod Med Biol. 2012. PMID: 29699125 Free PMC article. Review.

Saeidi S, Shapouri F, de Iongh RU, Casagranda F, Sutherland JM, Western PS, McLaughlin EA, Familari M, Hime GR. Saeidi S, et al. PLoS One. 2018 Jan 11;13(1):e0190925. doi: 10.1371/journal.pone.0190925. eCollection 2018. PLoS One. 2018. PMID: 29324788 Free PMC article.

Cite

Format: AMA APA MLA NLM

Read more here:
Pluripotent embryonic stem cells and multipotent adult germline stem ...

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.

Read the rest here:
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Intelligent Bio Solutions Inc. Announces Reverse Stock Split

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced a 1-for-20 reverse split of its common stock, effective at 5:00 P.M. Eastern Time today. Beginning on February 10, 2023, the Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “INBS”, but will trade under the following new CUSIP number: 36151G402.

Follow this link:
Intelligent Bio Solutions Inc. Announces Reverse Stock Split

Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.

See the original post:
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.

Read the original:
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

Mechelen, Belgium; 9 February 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 5th European CAR T-cell Meeting in Rotterdam.

Originally posted here:
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL